Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines (Q39820639)

14 September 2017

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines (English)

1 reference

14 September 2017

Y Kataoka

1

1 reference

14 September 2017

T Mukohara

2

1 reference

14 September 2017

H Shimada

3

1 reference

14 September 2017

N Saijo

4

1 reference

14 September 2017

M Hirai

5

1 reference

14 September 2017

H Minami

6

1 reference

14 September 2017

language of work or name

1 reference

24 July 2009

1 reference

14 September 2017

1 reference

14 September 2017

21

1 reference

14 September 2017

2

1 reference

14 September 2017

255-262

1 reference

ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics

14 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Rare cancer-specific mutations in PIK3CA show gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Relevance of breast cancer cell lines as models for breast tumours: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP304

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP304

1 reference

14 September 2017

1 reference